CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02910583
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:01.381284+00:00
Published At: 2022-02-18T00:00:00+00:00
Record Updated At: 2024-12-20
Results Posted At: 2022-02-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Leukemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-12-20"
protocolSection.identificationModule.nctId: "NCT02910583"
protocolSection.identificationModule.officialTitle: "Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-na\u00efve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-02-18"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.